Multidisciplinary management of advanced kidney cancer

Chad A. LaGrange, M. Dror Michaelson, Colleen H. Tetzlaff

Research output: Contribution to journalArticlepeer-review


A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor-based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.

Original languageEnglish (US)
Pages (from-to)977-981
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number75
StatePublished - Jul 2020

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Multidisciplinary management of advanced kidney cancer'. Together they form a unique fingerprint.

Cite this